BMED:MILBanca Mediolanum SpA Analysis
Data as of 2026-07-16 - not real-time
€22.48
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Banca Mediolanum is trading firmly above its short‑term moving averages, confirming a bullish bias despite a modest pullback in volume. Technical momentum remains strong, with the RSI positioned in the upper half of its range and price holding between well‑defined support and resistance zones. The MACD has turned slightly bearish, suggesting a short‑term cautionary note, but the overall trend remains upward.
The latest earnings release highlighted a solid increase in net income and a notable lift in operating margins, driven by core revenue strength and disciplined cost control. This earnings momentum, combined with a dividend yield that outpaces many peers, reinforces the stock’s attractiveness for income‑focused investors. Valuation metrics indicate the stock is priced below the sector average on a price‑to‑earnings basis, offering a margin of safety.
Given the low beta and moderate volatility, the share exhibits defensive characteristics, while the strong return on equity and sustainable payout ratio support a longer‑term upside narrative. Investors should monitor volume trends and the MACD signal for short‑term entry timing, but the fundamental backdrop remains robust.
The latest earnings release highlighted a solid increase in net income and a notable lift in operating margins, driven by core revenue strength and disciplined cost control. This earnings momentum, combined with a dividend yield that outpaces many peers, reinforces the stock’s attractiveness for income‑focused investors. Valuation metrics indicate the stock is priced below the sector average on a price‑to‑earnings basis, offering a margin of safety.
Given the low beta and moderate volatility, the share exhibits defensive characteristics, while the strong return on equity and sustainable payout ratio support a longer‑term upside narrative. Investors should monitor volume trends and the MACD signal for short‑term entry timing, but the fundamental backdrop remains robust.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price near resistance with limited upside in the near term
- Bearish MACD histogram indicating potential short‑term correction
- Decreasing volume suggesting reduced short‑term buying pressure
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong earnings growth and margin expansion
- Attractive dividend yield with a sustainable payout ratio
- Undervalued relative to sector PE and solid price performance above key moving averages
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Low beta and moderate volatility provide defensive qualities
- Consistent return on equity and robust capital position
- Favorable valuation gap combined with a high dividend yield supporting total return
Key Metrics & Analysis
Financial Health
Revenue Growth6.00%
Profit Margin52.05%
P/E Ratio13.1
ROE27.82%
ROA1.41%
P/B Ratio3.5
Industry P/E18.0
Technical Analysis
TrendBullish
RSI63.6
Support€21.23
Resistance€22.87
MA 20€22.19
MA 50€20.81
MA 200€18.89
MACDBearish
VolumeDecreasing
Fear & Greed Index91.55
Valuation
Target Price€22.98
Upside/Downside2.22%
GradeUndervalued
TypeValue
Dividend Yield5.78%
Risk Assessment
Beta0.44
Volatility19.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.